FOXO4-DRI
The first rationally designed senolytic peptide that selectively eliminates senescent cells by disrupting FOXO4-p53 interaction.
Also known as: Senolytic Peptide, D-Retro-Inverso
Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.
How It Works
D-retro-inverso peptide that penetrates cells and disrupts FOXO4-p53 protein interaction. Releases p53 from nuclear sequestration, leading to mitochondrial translocation and senescent cell-specific apoptosis.
Key Benefits
- ✓Selective senescent cell elimination
- ✓Reduced SASP inflammatory cytokines
- ✓Improved tissue homeostasis (preclinical)
- ✓Potential restoration of age-related function
- ✓No off-target toxicity to healthy cells (animal data)
Dosing Protocols
Beginner / Intermediate
Dose
5 mg/kg estimated
Frequency
IV dosing on Days 1, 3, 5
Cycle Length
3 weeks on, 3 weeks off
Notes
Only dose with published efficacy (animal models); human dosing unestablished
Advanced
Dose
5 mg/kg estimated
Frequency
Repeat cycles every 3-6 months
Cycle Length
Variable; minimal human data
Notes
No human clinical trials conducted; use experimental and physician-supervised only
Side Effects & Safety
Common Side Effects
- No serious toxicity in mouse models
- Theoretical: immune perturbation from senescent cell death
- Theoretical: off-target p53 effects
- Unknown in humans—no trials conducted
Contraindications
- Severe immunosuppression
- Active systemic infection
- No established human safety data
Stacking & Synergies
These compounds have complementary mechanisms and may enhance results when used together.
Key Takeaway
Remove the cellular zombies: FOXO4-DRI selectively triggers apoptosis in senescent cells for tissue rejuvenation.
Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.